UBQLNL Inhibitors
Chemical inhibitors of UBQLNL engage in a variety of interactions that can influence the function of this protein within cellular processes. Allopurinol, by inhibiting xanthine oxidase, can reduce the production of uric acid, which has been linked to purine metabolism pathways that may intersect with UBQLNL function. In a similar vein, MG-132, a proteasome inhibitor, prevents the degradation of ubiquitin-conjugated proteins, which can affect the turnover of proteins possibly regulated by UBQLNL. Chloroquine, known for raising lysosomal pH, disrupts protein degradation pathways that could indirectly limit the ability of UBQLNL to participate in protein turnover. Bortezomib and Carfilzomib, both potent proteasome inhibitors, interfere with the degradation process of the 26S proteasome, altering the cellular context for UBQLNL and potentially impacting its role in protein degradation.
Continuing with this theme, Eeyarestatin I targets the endoplasmic reticulum-associated degradation pathway by inhibiting protein dislocation from the ER, which may impede UBQLNL's involvement in these processes. Lactacystin, along with its active form Clasto-Lactacystin β-lactone, serves to inhibit the proteasome, thus impairing the degradation of polyubiquitinated proteins and influencing UBQLNL's functionality. MLN4924 takes a different approach by inhibiting NEDD8 activating enzyme, thereby affecting cullin-RING ligase function and potentially the ubiquitin-proteasome system where UBQLNL is implicated. Pyr-41, which irreversibly inhibits the ubiquitin activating enzyme E1, blocks the initial step of the ubiquitination cascade, which can indirectly influence UBQLNL's activity. Lastly, Epoxomicin selectively inhibits the proteasome's chymotrypsin-like activity, which could alter the proteasomal degradation pathway and, as a result, the functional dynamics of UBQLNL.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Allopurinol | 315-30-0 | sc-207272 | 25 g | $131.00 | ||
Allopurinol inhibits xanthine oxidase, an enzyme involved in purine metabolism. By reducing the production of uric acid, allopurinol can potentially lower the cellular concentrations of uric acid, which might otherwise contribute to the stabilization of UBQLNL through purine-dependent pathways. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a proteasome inhibitor that prevents the degradation of ubiquitin-conjugated proteins. While not directly inhibiting UBQLNL, by stabilizing the ubiquitin-proteasome system's substrates, it can influence the turnover of proteins potentially regulated by UBQLNL. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine raises lysosomal pH, which can disrupt the protein degradation pathways within the cell. Since UBQLNL is thought to be involved in ubiquitin-mediated processes, the disruption of lysosomal function could indirectly limit UBQLNL's ability to participate in protein turnover. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib specifically inhibits the 26S proteasome, again potentially increasing the levels of ubiquitinated proteins and influencing the cellular context in which UBQLNL operates, potentially leading to a functional inhibition of its role in protein turnover. | ||||||
Eeyarestatin I | 412960-54-4 | sc-358130B sc-358130 sc-358130A sc-358130C sc-358130D sc-358130E | 5 mg 10 mg 25 mg 50 mg 100 mg 500 mg | $114.00 $203.00 $354.00 $697.00 $1363.00 $5836.00 | 12 | |
Eeyarestatin I disrupts endoplasmic reticulum-associated degradation (ERAD) by inhibiting protein dislocation from the ER. Given UBQLNL's association with ubiquitin pathways, interference with ERAD might impede UBQLNL's function in this process. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is another proteasome inhibitor that impairs the degradation of polyubiquitinated proteins. It may indirectly inhibit UBQLNL function by altering the protein degradation pathway, where UBQLNL is potentially involved. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
MLN4924 inhibits NEDD8 activating enzyme, which is essential for cullin-RING ligase function, part of the ubiquitin-proteasome system. By hindering this system, it might indirectly affect UBQLNL's role within ubiquitin-mediated protein turnover. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
Pyr-41 is an irreversible inhibitor of ubiquitin activating enzyme E1. By blocking the initial step of the ubiquitination cascade, it could indirectly inhibit UBQLNL's ability to function within the ubiquitin-proteasome pathway. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin is a selective proteasome inhibitor that irreversibly binds to and inhibits the chymotrypsin-like activity of the proteasome. This could indirectly inhibit UBQLNL by altering the proteasomal degradation pathway. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
Carfilzomib is a proteasome inhibitor that is more potent and selective than Bortezomib. It could indirectly inhibit UBQLNL by modifying the activity of the ubiquitin-proteasome system and affecting protein turnover processes. | ||||||